S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias
SB1317 is designed to selectively inhibit major signalling pathwaysinvolving Flt3 and CDK, which impact disease progression in acute leukemias.Flt3 mutations are the most frequent genetic alterations reported in acutemyeloid leukemia (AML) patients and are associated with a poor prognosis. Inaddition, over-expression of wild type Flt3 has been found in acutelymphoblastic leukemia (ALL) patients. Cyclin-dependent kinases or CDKs playimportant roles in cell cycle control. By inhibiting both Flt3 and CDKkinases, SB1317 is uniquely positioned as a "first-in-class" compound to treatrelapsed and refractory acute leukemias. SB1317 has already enteredpreclinical development.
"The ability to maintain long-term control in AML and ALL remains one ofthe most significant unmet medical needs in the adult leukemia market. SB1317has been designed with this in mind, and we believe it has the potential tobecome a first of its kind Flt3 inhibitor to specifically target this group ofpatients," said Dr. Jan-Anders Karlsson, CEO of S*BIO, "With its ideal profilefor treating relapsed and refractory AML and ALL, SB1317 provides anopportunity for S*BIO to expand its portfolio of new targeted therapies forhematological disorders."
Approximately 300,000 new cases of leukemia are diagnosed worldwide eachyear, and there are about 36,000 new cases of acute leukemia in the sevenmajor pharmaceutical markets*. Acute leukemia is characterized by rapidgrowth and accumulation of immature blood cells in the bone marrow. Thisresults in fewer normal blood cells. Relapse rates following conventionalleukemia treatments remain high and limited treatment options exist forpatients who relapse after standard induction and post-remission chemotherapy.The 5 year overall survival rate for elderly patients with AML is 5-15% andabout 30% in younger adults*.
About S*BIO Pte Ltd
S*BIO is a privately-held biotech company focused on the research andclinical development of novel targeted small molecule drugs for the treatmentof cancer with leading programs around histone deacetylases (HDAC) andkinases. Its lead candidate, SB939, has entered the clinic in 2Q 2007. Itrecently announced that a second compound, SB1518, would enter the clinic in1H 2008.
In line with its vision to be a leading fully-integrated oncology-focusedbiotech company in Asia Pacific, S*BIO has established a state-of-the-art R&Dinfrastructure, complemented by a strong clinical development team. S*BIO hasstrong linkages with a network of medical oncologists in Asia Pacific and itsinvestors include Bio*One Capital, Novartis Bioventures and otherinternational funds. More information about S*BIO can be found atwww.sbio.com.S*BIO Pte Ltd: Stephen Keith Rhind, Ph.D. Senior Vice President, Corporate Development Tel: +65 6827 5000 (Singapore) Stephen_rhind@sbio.com Russo Partners: Tony Russo +1 212-845-4251 Tony.Russo@russopartnersllc.com Andreas Marathovouniotis +1 212-845-4253 Andreas.Marathis@russopartnersllc.com *source: Datamonitor
SOURCE S*BIO Pte Ltd
You May Also Like